SARS-CoV-2检测阳性成人长期症状研究
CDC利用非概率网络面板调查美国成人,比较自报SARS-CoV-2检测阳性者与阴性者的长期症状(>4周)患病率。加权阳性率为22.2%(95%CI 20.6%-23.8%),阳性者任何长期症状(65.9% vs 42.9%)、疲劳、嗅觉味觉改变、气短、咳嗽等患病率显著更高,且更多阳性者认为疫苗改善长期症状(28.7% vs 15.7%)。
要点
- 阳性者长期症状总患病率65.9%,显著高于阴性者42.9%。
- 嗅觉味觉改变差异最大(17.3% vs 1.7%),疲劳、气短、咳嗽也显著更高。
- 28.7%阳性者认为COVID-19疫苗改善长期症状,阴性者为15.7%。
核心结论
- 自报SARS-CoV-2检测阳性者长期症状患病率显著高于阴性者,需优化对持续症状患者的照护并传递疫苗接种潜在益处。
研究设计与样本
- CDC使用Porter Novelli Public Services建立的非概率网络面板,对全国≥18岁美国成人进行调查,比较自报曾阳性与始终阴性者的长期症状(自起病>4周)患病率。
主要发现
- 加权阳性率为22.2%(95%CI 20.6%-23.8%)。
- 阳性者中约三分之二经历常与SARS-CoV-2感染相关的长期症状。
- 阳性者vs阴性者:任何长期症状65.9% vs 42.9%,疲劳22.5% vs 12.0%,嗅觉味觉改变17.3% vs 1.7%,气短15.5% vs 5.2%,咳嗽14.5% vs 4.9%,头痛13.8% vs 9.9%,至少一种初始症状持续>4周76.2% vs 69.6%。
- 阳性者中28.7%认为COVID-19疫苗使长期症状好转,阴性者中为15.7%。
临床怎么用
- 帮助卫生专业人员识别最常见新冠后状况并优化持续症状患者的照护。
- 向患者传递COVID-19疫苗接种对长期症状潜在益处的信息。
局限性
- 使用非概率网络面板,可能影响样本代表性。
- 基于自报检测结果与症状,可能存在回忆偏倚与错分。
- 原文指出既往研究较少与检测阴性普通成人比较,限制背景症状患病率评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term symptoms often associated with COVID-19 (post-COVID conditions or long COVID) are an emerging public health concern that is not well understood. Prevalence of post-COVID conditions has been reported among persons who have had COVID-19 (range = 5%-80%), with differences possibly related to different study populations, case definitions, and data sources (1). Few studies of post-COVID conditions have comparisons with the general population of adults with negative test results for SARS-CoV-2, the virus that causes COVID-19, limiting ability to assess background symptom prevalence (1). CDC used a nonprobability-based Internet panel established by Porter Novelli Public Services* to administer a survey to a nationwide sample of U.S. adults aged ≥18 years to compare the prevalence of long-term symptoms (those lasting >4 weeks since onset) among persons who self-reported ever receiving a positive SARS-CoV-2 test result with the prevalence of similar symptoms among persons who reported always receiving a negative test result. The weighted prevalence of ever testing positive for SARS-CoV-2 was 22.2% (95% confidence interval [CI] = 20.6%-23.8%). Approximately two thirds of respondents who had received a positive test result experienced long-term symptoms often associated with SARS-CoV-2 infection. Compared with respondents who received a negative test result, those who received a positive test result reported a significantly higher prevalence of any long-term symptom (65.9% versus 42.9%), fatigue (22.5% versus 12.0%), change in sense of smell or taste (17.3% versus 1.7%), shortness of breath (15.5% versus 5.2%), cough (14.5% versus 4.9%), headache (13.8% versus 9.9%), and persistence (>4 weeks) of at least one initially occurring symptom (76.2% versus 69.6%). Compared with respondents who received a negative test result, a larger proportion of those who received a positive test result reported believing that receiving a COVID-19 vaccine made their long-term symptoms better (28.7% versus 15.7%). Efforts to address post-COVID conditions should include helping health care professionals recognize the most common post-COVID conditions and optimize care for patients with persisting symptoms, including messaging on potential benefits of COVID-19 vaccination.
引用
- Wanga V, Chevinsky JR, Dimitrov LV, et al. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34499626. doi:10.15585/mmwr.mm7036a1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。